Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price Target

Needham analyst Gil Blum has reiterated a Buy rating on Nurix Therapeutics (NASDAQ: NRIX) and maintained a price target of $34 for the stock. No specific financial figures or market impacts were mentioned in the article.